RM-MET / Metabolic and incretin signalling
Lixisenatide
Also known as: Adlyxin · Lyxumia · AVE0010 · ZP10
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Lixisenatide is a 44-amino-acid GLP-1 receptor agonist derived from exendin-4. The library separates it from other incretin agonists and from combination products.
Evidence position
The FDA-labeled injection and human evidence support Grade A for the regulated presentation.
What the record does not establish
That record does not authenticate a separately sourced material or transfer device, sterility and formulation controls.
Sources
- 01Lixisenatide compound recordPubChem
- Shows
- Registry identity, structure, formula and development synonyms for lixisenatide
- Does not show
- Does not establish device, formulation, sterility or lot quality
- 02Adlyxin prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. label for a defined lixisenatide injection pen
- Does not show
- Does not qualify another concentration, device, source or peptide sample
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Lixisenatide
- CID
- 90472060
- Formula
- C215H347N61O65S
- Mass
- 4858
PUBMED / FOUND RECORDS
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.Molecular metabolism / 2021 AprPMID 33068776 / DOI 10.1016/j.molmet.2020.101102
- Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.International journal of molecular sciences / 2023 Jun 21PMID 37445623 / DOI 10.3390/ijms241310449
- Trial of Lixisenatide in Early Parkinson's Disease.The New England journal of medicine / 2024 Apr 4PMID 38598572 / DOI 10.1056/NEJMoa2312323
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.The New England journal of medicine / 2015 Dec 3PMID 26630143 / DOI 10.1056/NEJMoa1509225
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.Journal of the American College of Cardiology / 2025 Nov 18PMID 40892610 / DOI 10.1016/j.jacc.2025.08.027
CLINICALTRIALS.GOV / FOUND RECORDS
- Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanCOMPLETED / PHASE4 / SanofiNCT02941367 / DIRECT intervention MATCH: Lixisenatide
- Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid SecretionTERMINATED / PHASE1 / Profil Institut für Stoffwechselforschung GmbHNCT02231658 / DIRECT intervention MATCH: Lixisenatide
- GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCOMPLETED / PHASE3 / SanofiNCT00712673 / DIRECT intervention MATCH: Lixisenatide
- Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsTERMINATED / PHASE3 / SanofiNCT03434119 / DIRECT intervention MATCH: Lixisenatide
- Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 DiabetesCOMPLETED / PHASE2 / SanofiNCT01175473 / DIRECT intervention MATCH: Lixisenatide